NIMble innovation—a networked model for public antibiotic trials


11 Oct 2021
Rebecca E Glover, PhD, Andrew C Singer, PhD, Adam P Roberts, PhD, Claas Kirchhelle, PhD

DOI:https://doi.org/10.1016/S2666-5247(21)00182-8

Summary:

Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model’s benefits for unblocking the public and private antibiotic pipeline.


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.